The company, which is developing treatments for eye diseases, has raised $330 million from investors as it readies for late-stage testing.
A startup developing treatments for eye diseases has raised $330 million from investors as it readies for late-stage testing.
Ollin Biosciences is about to begin a Phase 3 trial of a treatment for both diabetic macular edema and wet age-related macul... [521 chars]